Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany.
Department of Stress Neurobiology and Neurogenetics, Max Planck Institute of Psychiatry, Munich, Germany.
Nat Chem Biol. 2015 Jan;11(1):33-7. doi: 10.1038/nchembio.1699. Epub 2014 Dec 1.
The FK506-binding protein 51 (FKBP51, encoded by the FKBP5 gene) is an established risk factor for stress-related psychiatric disorders such as major depression. Drug discovery for FKBP51 has been hampered by the inability to pharmacologically differentiate against the structurally similar but functional opposing homolog FKBP52, and all known FKBP ligands are unselective. Here, we report the discovery of the potent and highly selective inhibitors of FKBP51, SAFit1 and SAFit2. This new class of ligands achieves selectivity for FKBP51 by an induced-fit mechanism that is much less favorable for FKBP52. By using these ligands, we demonstrate that selective inhibition of FKBP51 enhances neurite elongation in neuronal cultures and improves neuroendocrine feedback and stress-coping behavior in mice. Our findings provide the structural and functional basis for the development of mechanistically new antidepressants.
FK506 结合蛋白 51(FKBP51,由 FKBP5 基因编码)是与应激相关的精神疾病(如重度抑郁症)的既定风险因素。由于无法在药理学上区分结构相似但功能相反的同源物 FKBP52,FKBP51 的药物发现受到了阻碍,而且所有已知的 FKBP 配体都是非选择性的。在这里,我们报告了 FKBP51 的强效和高选择性抑制剂 SAFit1 和 SAFit2 的发现。这种新的配体通过诱导契合机制实现对 FKBP51 的选择性,而这种机制对 FKBP52 则不太有利。通过使用这些配体,我们证明选择性抑制 FKBP51 可增强神经元培养物中的神经突伸长,并改善小鼠的神经内分泌反馈和应激应对行为。我们的发现为开发具有全新作用机制的抗抑郁药提供了结构和功能基础。